Company Overview and News


Add ONTX
to your dashboard

Headline News

Your Daily Pharma Scoop: Adamas's Gocovri, Onconova To Advance INSPIRE Study, Agios Initiates Public Offering

14h seekingalpha
Today, we will Adamas Pharmaceuticals (ADMS) and the potential of company's Gocovri, which was approved by the FDA last year for the treatment of levodopa-induced dyskinesia in Parkinson's Disease (PD) patients. (210-1)

Your Daily Pharma Scoop: Adamas' Gocovri, Onconova To Advance INSPIRE Study, Agios Initiates Public Offering

14h seekingalpha
Today we will Admas Pharmaceuticals' (ADMS) and the potential of company's Gocovri, which was approved by the FDA last year for the treatment of levodopa-induced dyskinesia in Parkinson's Disease (PD) patients. (210-0)

U.S. Biotech/Pharma Sector Daily Observations Letter: January 17, 2018

2018-01-18 seekingalpha
Broad U.S. equities including the biotech sector resumed the uptrend today, but we are very extended here. (69-0)

ONTX / Onconova Therapeutics, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-01-09 fintel.io
Onconova Therapeutics, Inc. (NASDAQ:ONTX) has 14 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 2,459,681 shares. Largest shareholders include Tyndall Capital Partners L P, Sabby Management, LLC, 683 Capital Management, LLC, Boxer Capital, LLC, Renaissance Technologies LLC, Vanguard Group Inc, Panagora Asset Management Inc, Virtu Financial LLC, UBS Group AG, and BlackRock Inc. (66-0)

Wired News – Onconova Signs License and Collaborative Development Agreement with HanX Biopharma for ON 123300

2017-12-21 accesswire
LONDON, UK / ACCESSWIRE / December 21, 2017 / Active-Investors.com has just released a free report on Onconova Therapeutics, Inc. (NASDAQ: ONTX) ("Onconova"). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ONTX. On December 19, 2017, the Phase-3-stage biopharmaceutical Company, working towards discovering and developing small molecule drug candidates to treat cancer, with a focus on Myelodysplastic Syndromes (MDS), declared that it has entered into a license and collaboration agreement with the oncology specialty Company HanX Biopharmaceuticals Inc. (31-0)

Your Daily Pharma Scoop: Valeant Still Risky, Onconova Signs Agreement, Array Biopharma Announces Collaboration

2017-12-20 seekingalpha
Today we will discuss an article on Valeant (VRX) by Michael Wiggins De Oliveira, titled, “Valeant: I Was Serious – The Clock Is Ticking.” (334-4)

BRIEF-Onconova Therapeutics files for mixed shelf offering of upto $84.5 mln

2017-11-20 reuters
* Onconova Therapeutics Inc files for mixed shelf offering of upto $84.5 million- SEC filing‍​ Source text: (bit.ly/2AiGwl1) Further company coverage: (26-1)

BRIEF-Onconova Therapeutics announces data on improved formulation of Rigosertib and next-generation CDK4/6 inhibitor

2017-11-16 reuters
* Onconova Therapeutics announces data on improved formulation of Rigosertib and next-generation CDK4/6 inhibitor at 2017 American Association Of Pharmaceutical Scientists annual meeting Source text for Eikon: Further company coverage: (26-0)

Your Daily Pharma Scoop: Neurocrine Has Upside, Dynavax Gets FDA Nod, Sage Soars

2017-11-12 seekingalpha
This abridged “Daily Scoop” is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (340-6)

Cellectar Biosciences' (CLRB) CEO Jim Caruso on Q3 2017 Results - Earnings Call Transcript

2017-11-10 seekingalpha
Good day, ladies and gentlemen and welcome to the Cellectar Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference call is being recorded. (43-3)

Your Daily Pharma Scoop: MannKind Is A Trade Not An Investment; AstraZeneca's Imfinzi

2017-10-10 seekingalpha
This abridged "Daily Scoop" is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. (647-3)

BRIEF-Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics

2017-09-21 reuters
* Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics to develop new phospholipid drug conjugates (43-0)

Onconova Therapeutics' (ONTX) CEO Ramesh Kumar on Q2 2017 Results - Earnings Call Transcript

2017-08-15 seekingalpha
Good morning, and welcome to Onconova’s Second Quarter 2017 Earnings Call and Webcast. At this time, all participants have been placed on listen-only mode. At the end of the prepared statements, participants will have the opportunity to ask questions. [Operator instructions]

BRIEF-Onconova Therapeutics announces research and clinical programs evaluating rigosertib in pediatric “rasopathies”

2017-07-25 reuters
* Onconova Therapeutics announces establishment of collaborative research and clinical programs evaluating rigosertib in pediatric “rasopathies”

CUSIP: 68232V108